139 related articles for article (PubMed ID: 29348764)
21. [Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing shen and strenghening pi].
Xu S; Hu XM; Xu YG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Mar; 28(3):216-8. PubMed ID: 18476419
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacokinetics and urinary excretion of arsenic and mercury after oral administration of realgar, cinnabar and AnGongNiuHuang Pill to rats.
Wu X; Zhong Z; Lin K; Liu X; Wu Z; Liu Z; Li Y
Front Pharmacol; 2022; 13():967608. PubMed ID: 36110533
[TBL] [Abstract][Full Text] [Related]
23. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.
Hu XM; Liu F; Ma R
Chin J Integr Med; 2010 Aug; 16(4):368-77. PubMed ID: 20697951
[TBL] [Abstract][Full Text] [Related]
24. Study of the accumulation and distribution of arsenic species and association with arsenic toxicity in rats after 30 days of oral realgar administration.
Yi Y; Gao S; Xia J; Li C; Zhao Y; Zhang Y; Liang A; Ji S
J Ethnopharmacol; 2020 Jan; 247():111576. PubMed ID: 30385423
[TBL] [Abstract][Full Text] [Related]
25. Use status and metabolism of realgar in Chinese patent medicine.
Li Y; Wang D; Xu Y; Liu B; Zheng Y; Yang B; Fan S; Zhi X; Zheng Q; Sun G
J Ethnopharmacol; 2015 Apr; ():. PubMed ID: 25861951
[TBL] [Abstract][Full Text] [Related]
26. [Asenic accumulation following realgar administration in rats].
Li C; Liang A; Wang J; Xue B; Li H; Yang B; Wang J; Xie Q; Nilsen OG; Zhang B
Zhongguo Zhong Yao Za Zhi; 2011 Jul; 36(14):1895-900. PubMed ID: 22016955
[TBL] [Abstract][Full Text] [Related]
27. Health risk assessment of arsenic in Realgar and NiuHuangJieDu Tablets based on pharmacokinetic study.
Wu X; Wu S; Liu Y; Guan R; Liang F; Song M; Hang T
J Trace Elem Med Biol; 2018 Jul; 48():81-86. PubMed ID: 29773199
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Efficacy of Low-Dose Decitabine alone for Treatment of Myelodysplastic Syndrome].
Shi R; Guo SQ; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1568-1573. PubMed ID: 31607313
[TBL] [Abstract][Full Text] [Related]
29. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
30. Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro.
Xu M; Ren JY; Guo YC; Xu BX; Zeng Q; Hu Q; Zhou YM; Lu JH
Leuk Res; 2017 Nov; 62():4-11. PubMed ID: 28963909
[TBL] [Abstract][Full Text] [Related]
31. [Toxicity study of realgar].
Liang A; Li C; Wang J; Xue B; Li H; Yang B; Wang J; Xie Q; Nilsen OG
Zhongguo Zhong Yao Za Zhi; 2011 Jul; 36(14):1889-94. PubMed ID: 22016954
[TBL] [Abstract][Full Text] [Related]
32. Realgar (α-As
Zhang M; Zhang JY; Sun MQ; Lu P; Liu JX
Chin J Integr Med; 2022 Mar; 28(3):281-288. PubMed ID: 32418175
[TBL] [Abstract][Full Text] [Related]
33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
34. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding.
Wu JZ; Ho PC
Eur J Pharm Sci; 2006 Sep; 29(1):35-44. PubMed ID: 16824739
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
37. The alleviation effect and its mechanism of Niuhuang Jiedu prescription on realgar-induced genotoxicity in mice.
Dong J; Wang Y; Qian Q; Wu J; Yang D; Liu D
J Ethnopharmacol; 2024 Jun; 333():118426. PubMed ID: 38844250
[TBL] [Abstract][Full Text] [Related]
38. Research progress on arsenic, arsenic-containing medicinal materials, and arsenic-containing preparations: clinical application, pharmacological effects, and toxicity.
Yang Y; Li Y; Li R; Wang Z
Front Pharmacol; 2024; 15():1338725. PubMed ID: 38495096
[No Abstract] [Full Text] [Related]
39. [Preliminary study of Realgar and arsenic trioxide on gut microbiota of mice].
Sun YT; Xu HH; Nie Y; Wang YG; Ma ZC; Zhou W; Tan HL; Gao Y
Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):142-148. PubMed ID: 32237423
[TBL] [Abstract][Full Text] [Related]
40. A cultural practice of drinking realgar wine leading to elevated urinary arsenic and its potential health risk.
Zhang YN; Sun GX; Huang Q; Williams PN; Zhu YG
Environ Int; 2011 Jul; 37(5):889-92. PubMed ID: 21450346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
